Latest news
Maxion Therapeutics Highly Commended in ‘Employer of the Year’ Category at Cambridge Independent Science and Technology Awards
Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO
Maxion Therapeutics’ Breakthrough Science and Innovation Recognised in PwC UK’s Life Sciences Future50 list
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Maxion Therapeutics Expands Team and Facilities with Move to Unity Campus
Maxion Therapeutics Wins ‘Start-up of the Year’ at 2023 Cambridge Independent Science & Technology Awards
Maxion Therapeutics Awarded £2 million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-to-Treat" Autoimmune Diseases
Maxion Therapeutics’ $16 million pre-Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Maxion Therapeutics strengthens its Board with the appointment of Ian Tomlinson (Chairman), Tom Weaver (Non-Executive Director), and Aneesh Karatt Vellatt (Director)
News
